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ABSTRACT
The objective of this study was to report a case of a person with psychiatric illness treated with clozapine presented with diabetic ketoacidosis (DKA). 
A clinical monitoring was done on a 38-year-old Indian man affected by schizoaffective disorder, bipolar type presented with DKA after 3 months of 
clozapine therapy (250 mg/day). After treatment of DKA and discontinuation of clozapine, the patient improved symptomatically, his blood sugar 
levels normalized and insulin requirements also decreased. This report thus highlights that clinicians should be vigilant about the potential risk of 
new-onset diabetes and DKA in patients taking clozapine and utilize appropriate clinical and laboratory monitoring early in the course of treatment 
to prevent serious adverse effects.
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INTRODUCTION
Clozapine is an atypical antipsychotic indicated for the management 
of treatment-resistant schizophrenia and to reduce the suicidal 
behavior in patients with schizophrenia or schizoaffective disorder. 
Hyperglycemia, in some cases associated with ketoacidosis or 
hyperosmolar coma or death, has been reported in patients treated 
with atypical antipsychotics including clozapine [1-5]. This is the case 
report of a man affected by schizoaffective disorder, bipolar type who 
developed Type 2 diabetes mellitus and diabetic ketoacidosis (DKA) 
while on clozapine for a duration of 3 months, but in our case, it was 
noted that even after adequate glycemic control, the acidosis took a 
relatively longer period to normalize.
METHODOLOGY
Informed consent was taken as per the institutional policy.
CASE REPORT
A 38-year-old man of Indian descent affected by schizoaffective 
disorder, bipolar type was admitted with complaints of vomiting, 
headache, and fever for 4 days. Initially, the patient was admitted in 
a local hospital where his blood sugar was >600 mg/dl and managed 
with insulin infusion and referred to AIMS. This patient had a history of 
psychiatric illness for nearly 20 years and was on and off medications 
for the same. The patient was started on clozapine therapy before 
3 months considering the severity of his psychotic symptoms and 
suicidal ideation. On initiation of therapy, his random serum glucose 
level was 111.9 mg/dL.
At the time of admission to our center, his random glucose was 378 mg/dl. 
However, his acidosis persisted. He was dehydrated and laboratory data 
revealed his glycosylated hemoglobin was 14%. Arterial blood gases 
showed pH 7.15, pCO2 17.3 mmHg, pO2 121 mmHg, and bicarbonate 
9.8 mmol/L. Serum and urinary ketones were positive. Routine blood 
investigations revealed normal counts with mild elevation of serum 
creatinine (1.54 mg/dL) and C-reactive protein (18.6 mg/L). Serum 
sodium and potassium levels at admission were 134.4 mmol/L and 
4.2 mmol/L, respectively. He was managed with intravenous potassium 
infusions to maintain target serum K+levels as per DKA protocol. His 
detailed arterial blood gas values for 3 days are represented in Table 1. 
Computed tomography scan of the brain was normal. Toxicological 
analysis of urine, blood, and gastric aspirate was done. The urine 
sample was positive for clozapine. Clozapine was discontinued. Over 
the next 3 days, the patient improved symptomatically, his blood sugar 
levels normalized and insulin requirements also decreased. His acidosis 
and anion gap took 72 h to normalize. Following this, a psychiatric 
consultation was taken and aripiprazole was initiated. The patient was 
discharged after 12 days on a diabetic diet, metformin, human insulin, 
and isophane insulin. At the time of discharge, his serum glucose level 
was 134 mg/dL. The patient came for review after 1 week of discharge 
and his fasting blood sugar was 69.7 and post prandial blood sugar 
(PPBS) was 175 mg/dL. His insulin requirement decreased to biphasic 
isophane insulin.
DISCUSSION
Atypical antipsychotics have demonstrated a significant advantage 
over conventional antipsychotics not only in terms of clinical efficacy 
but also safety, with lower incidence of extrapyramidal symptoms and 
tardive dyskinesia. However, there have been numerous case reports, 
epidemiological data suggesting that certain atypical antipsychotics 
may be associated with a greater risk of metabolic abnormalities than 
others including weight gain, hyperlipidemia, and new onset Type 2 
diabetes mellitus or DKA [6]. Among atypical antipsychotics currently 
in use, clozapine and olanzapine are known to have the highest risk of 
metabolic complications [2,3].
DKA, an acute metabolic complication of diabetes, although appears to 
be uncommon, is of great concern secondary to the risk of death. The 
incidence of diabetes presenting as DKA in schizophrenia patients is 
almost 10-fold higher than that reported in the general population [3].
The risk factors for the development of DKA during clozapine treatment 
are unclear since clozapine treatment has been associated with DKA 
even in patients with no documented history of hyperglycemia, 
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diabetes, or weight gain. However, people of African American or 
African Caribbean descent have been reported to be more susceptible 
to this adverse effect [2,4,7,8]. In our case, apart from a family history of 
diabetes, the patient had no other predisposing factor. He had no weight 
gain during treatment; hence, this cannot be implicated in the onset of 
DKA.
DKA has been reported to typically occur early in the course of 
treatment, with high proportion of patients developing it within 
3 months of clozapine initiation [4,9-11]. In our case also, it took 
nearly 3 months before a diagnosis of ketoacidosis was made. However, 
elevated glycosylated hemoglobin levels observed at admission suggest 
that the patient had impaired glucose tolerance for at least several 
weeks before the DKA episode.
The association between clozapine and DKA does not appear to be 
dose dependent. In the reported cases of DKA, among clozapine-
treated patients, clozapine doses have ranged from 150 mg/day 
to 500 mg/day [7,9,11]. Our patient developed DKA while taking 
250 mg/day of clozapine for 3 months.
Assessment of the relationship between atypical antipsychotic use 
and glucose abnormalities is complicated by the possibility of an 
increased background risk of diabetes mellitus in patients with 
schizophrenia. However, the occurrence of cases of new or worsening 
diabetes mellitus and DKA in patients using clozapine suggests 
a causal relationship. The mechanism by which clozapine causes 
diabetes and other metabolic disturbances are not fully understood 
but could involve insulin resistance, suppression of insulin release, 
or impairments in glucose utilization, leading to the development of 
abnormal glucose tolerance, which can be clinically manifested as a 
spectrum ranging from impaired glucose tolerance through severe 
hyperglycemia to DKA [12].
Reports and clinical experience suggest that in a case of clozapine-
associated diabetes or DKA, discontinuation of the drug may result 
in resolution of the hyperglycemia and diabetes [7,9,11]. Consistent 
with the same, in our patient, after supportive treatment involving 
discontinuation of medication and intensive glycemic control, the 
metabolic parameters and clinical symptoms were restored in a 
short time, indicating that the effects of clozapine-induced metabolic 
complications are reversible. However, in our case, it was also noted 
that even after adequate glycemic control, the acidosis took a relatively 
longer period to normalize.
CONCLUSION
Clozapine-related DKA can occur soon after treatment and can persist 
several days, irrespective of ethnic origin, in the absence of family history 
of diabetes or weight gain, and does not also appear to be dose dependent. 
The 1st 3–6 months of clozapine treatment appear to be a high-risk 
period. Although the occurrence of DKA is rare, in our case, it persisted 
3 days. Clinicians must remain vigilant given its acute onset and potential 
lethality and should utilize appropriate clinical and laboratory monitoring 
early in the course of treatment to prevent serious adverse effects as 
discontinuation of the drug is of paramount importance in management.
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Table 1: Arterial blood gas values during the DKA period (1st 3 days)
Values Day1 Day 2 Day 3
Plasma glucose (mg/dL) 187 225 207 189 149 171 208 147 94
Arterial pH 7.16 7.14 7.14 7.19 7.17 7.21 7.26 7.34 7.34
Serum bicarbonate (mmol/L) 10.7 10.3 9.3 11.8 10.7 12.8 13.9 18.2 17.9
Lactate (mmol/L) 0.6 0.6 0.8 0.6 0.5 0.6 0.7 0.8 0.6
PCO2 (mmHg) 21.4 21.3 18.5 24.1 22.8 28.7 25.3 29.5 30.8
DKA: Diabetic ketoacidosis
1. US Prescribing Information of CLOZARIL® (clozapine) Tablets, 
for Oral Use;2014.Availablefrom:https://www.pharma.us.novartis.com/
product/pi/pdf/Clozaril.pdf. [Last accessed on 2014 Sep ].
